title: Exposure of human lung cancer cells to 8-chloro-adenosine induces G2/M arrest and mitotic catastrophe.
abstract: 8-Chloro-adenosine (8-Cl-Ado) is a potent chemotherapeutic agent whose cytotoxicity in a variety of tumor cell lines has been widely investigated. However, the molecular mechanisms are uncertain. In this study, we found that exposure of human lung cancer cell lines A549 (p53-wt) and H1299 (p53-depleted) to 8-Cl-Ado induced cell arrest in the G2/M phase, which was accompanied by accumulation of binucleated and polymorphonucleated cells resulting from aberrant mitosis and failed cytokinesis. Western blotting showed the loss of phosphorylated forms of Cdc2 and Cdc25C that allowed progression into mitosis. Furthermore, the increase in Ser10-phosphorylated histone H3-positive cells revealed by fluorescence-activated cell sorting suggested that the agent-targeted cells were able to exit the G2 phase and enter the M phase. Immunocytochemistry showed that microtubule and microfilament arrays were changed in exposed cells, indicating that the dynamic instability of microtubules and microfilaments was lost, which may correlate with mitotic dividing failure. Aberrant mitosis resulted in mitotic catastrophe followed by varying degrees of apoptosis, depending on the cell lines. Thus, 8-Cl-Ado appears to exert its cytotoxicity toward cells in culture by inducing mitotic catastrophe.
authors.affiliation: Department of Biochemistry and Molecular Biology, Peking University Health Science Center, Xue Yuan Road 38, Beijing 100083, PR China.
authors.forename: Hong-Yu
authors.initials: HY
authors.lastname: Zhang
authors.forename: Yan-Yan
authors.initials: YY
authors.lastname: Gu
authors.forename: Zeng-Gang
authors.initials: ZG
authors.lastname: Li
authors.forename: Yu-Hong
authors.initials: YH
authors.lastname: Jia
authors.forename: Lan
authors.initials: L
authors.lastname: Yuan
authors.forename: Shu-Yan
authors.initials: SY
authors.lastname: Li
authors.forename: Guo-Shun
authors.initials: GS
authors.lastname: An
authors.forename: Ju-Hua
authors.initials: JH
authors.lastname: Ni
authors.forename: Hong-Ti
authors.initials: HT
authors.lastname: Jia
mesh_terms: D000241:Adenosine / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D002453:Cell Cycle / Q000187:drug effects*; D045744:Cell Line, Tumor; D005434:Flow Cytometry; D006131:Growth Inhibitors / Q000494:pharmacology*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008938:Mitosis / Q000187:drug effects*
chemical_list: D006131:Growth Inhibitors; D000241:Adenosine
references.citation: Blood. 1998 Oct 15;92(8):2893-8
references.pmid: 9763575
references.citation: J Cell Sci. 2000 Nov;113 Pt 21:3681-2
references.pmid: 11034894
references.citation: Cancer Res. 1989 Oct 15;49(20):5650-5
references.pmid: 2676146
references.citation: Neoplasia. 2000 Sep-Oct;2(5):441-8
references.pmid: 11191111
references.citation: Clin Cancer Res. 2002 Aug;8(8):2735-41
references.pmid: 12171907
references.citation: J Cell Biol. 1995 Jan;128(1-2):117-25
references.pmid: 7822409
references.citation: Neurosci Lett. 2003 Dec 4;352(2):105-8
references.pmid: 14625034
references.citation: Curr Biol. 1998 Jul 30-Aug 13;8(16):903-13
references.pmid: 9707401
references.citation: J Biol Chem. 2001 Jun 15;276(24):21529-37
references.pmid: 11278991
references.citation: Cancer Res. 2003 Nov 15;63(22):7968-74
references.pmid: 14633728
references.citation: Clin Cancer Res. 1995 Apr;1(4):377-84
references.pmid: 9815994
references.citation: Int J Cancer. 2001 Jul 1;93(1):33-41
references.pmid: 11391618
references.citation: Science. 1994 Dec 16;266(5192):1821-8
references.pmid: 7997877
references.citation: Nat Cell Biol. 1999 Jul;1(3):E73-9
references.pmid: 10559915
references.citation: J Biol Chem. 1993 Mar 15;268(8):5774-82
references.pmid: 8449943
references.citation: Cancer Invest. 2002;20(7-8):972-82
references.pmid: 12449730
references.citation: Cancer Res. 2001 Jul 15;61(14):5474-9
references.pmid: 11454694
references.citation: Cancer Res. 1993 Jan 15;53(2):393-400
references.pmid: 8380255
references.citation: Nature. 2003 May 29;423(6939):493, 495
references.pmid: 12774110
references.citation: Nature. 2003 Apr 17;422(6933):753-8
references.pmid: 12700769
references.citation: Prog Cell Cycle Res. 2000;4:107-14
references.pmid: 10740819
references.citation: Nature. 2003 Apr 17;422(6933):746-52
references.pmid: 12700768
references.citation: J Clin Invest. 1999 Dec;104(12):1645-53
references.pmid: 10606615
references.citation: Nature. 2001 May 3;411(6833):102-7
references.pmid: 11333986
references.citation: Nature. 2000 Jul 27;406(6794):430-5
references.pmid: 10935642
references.citation: Cancer Res. 2001 Feb 15;61(4):1327-33
references.pmid: 11245429
references.citation: Chromosoma. 1997 Nov;106(6):348-60
references.pmid: 9362543
references.citation: Drug Resist Updat. 2001 Oct;4(5):303-13
references.pmid: 11991684
references.citation: Cell. 2003 Apr 4;113(1):87-99
references.pmid: 12679037
references.citation: Oncogene. 2003 Sep 1;22(37):5834-47
references.pmid: 12947390
references.citation: Nat Cell Biol. 2000 Feb;2(2):90-5
references.pmid: 10655588
references.citation: Exp Cell Res. 2000 Mar 15;255(2):321-6
references.pmid: 10694447
references.citation: Exp Cell Res. 2000 Aug 25;259(1):64-78
references.pmid: 10942579
references.citation: Cell Res. 2002 Dec;12(5-6):395-400
references.pmid: 12528897
references.citation: Nature. 2003 Aug 28;424(6952):1074-8
references.pmid: 12904818
references.citation: Methods Cell Biol. 1999;61:267-95
references.pmid: 9891320
references.citation: Clin Cancer Res. 2001 Feb;7(2):320-30
references.pmid: 11234887
references.citation: Cancer Res. 1992 Jul 15;52(14):3994-9
references.pmid: 1617676
references.citation: Nucleosides Nucleotides Nucleic Acids. 2002;21(8-9):599-617
references.pmid: 12484453
references.citation: Anticancer Drugs. 1992 Oct;3(5):485-91
references.pmid: 1450443